NovoNordisk CEO Lars Fruergaard Joergensen in December during a presentation of a new production site. The company's latest attempt at a weight loss drug, CagriSema, matched the bar set by a ...
NovoNordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.
NovoNordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...
Results that may be inaccessible to you are currently showing.